Analyses of Exosomal HER2 in Breast Cancer and the Effect of Respective Exosome-Immune Complexes on Trastuzumab-Based Immunotherapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110331 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jordan Gorospe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Product Quality Research IV, Office of Pharmaceutical Quality and Research, Center for Drug Evaluation Research, Food and Drug Administra…. Hauptthemen laut MEDLINE: Trastuzumab, Exosomes, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Office of Pharmaceutical Quality -Immunology COE.
Abstract (Originalsprache)
Monoclonal antibodies like trastuzumab have shown clinical success in cancer treatment, but patient responses vary, and resistance can develop, possibly due to tumor microenvironment factors. In this study, we explored the role of HER2-positive exosomes in counteracting one of the mechanisms of action of trastuzumab: antibody-dependent cell-mediated cytotoxicity (ADCC). We conducted a comprehensive analysis of HER2 expression on exosomes purified from the plasma of breast cancer patients and different breast cancer cell lines using various purification methods. Purified exosomes were analyzed using the single-particle interferometric reflectance imaging sensor (SP-IRIS)-based ExoView platform. To gain better insight into the formation of exosomal-immune complexes with trastuzumab, we used the ExoView platform to analyze the CD9/HER2/Human IgG phenotype of exosomes at the single vesicle level. Additionally, in a standard functional ADCC assay, formation of exosome-immune complexes with trastuzumab reduced the killing of breast cancer target cells. Together, our findings show that exosomes can function as decoys for immunotherapy, reducing its efficacy, and that SP-IRIS-based analysis can be used to identify levels of HER2-expressing exosomes in patients, which could aid in patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Product Quality Research IV, Office of Pharmaceutical Quality and Research, Center for Drug Evaluation Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Förderung
- Office of Pharmaceutical Quality -Immunology COE
Zitieren
APA
Gorospe, J., Shapiro, M., & Simhadri, V. R. (2025). Analyses of Exosomal HER2 in Breast Cancer and the Effect of Respective Exosome-Immune Complexes on Trastuzumab-Based Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110331
Vancouver
Gorospe J, Shapiro M, Simhadri VR. Analyses of Exosomal HER2 in Breast Cancer and the Effect of Respective Exosome-Immune Complexes on Trastuzumab-Based Immunotherapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110331
BibTeX
@article{Gorospe2025,
author = {Gorospe, Jordan and Shapiro, Marjorie and Simhadri, Venkateswara R},
title = {Analyses of Exosomal HER2 in Breast Cancer and the Effect of Respective Exosome-Immune Complexes on Trastuzumab-Based Immunotherapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110331}
}
EUVIMED